Angiogenesis: an organizing principle for drug discovery?

By J. Folkman. Nature reviews. Drug discovery, 2007

1,270 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/3b7bf686ce9d06284ab974168eb2ac95c7538017

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (2013, background): “Finally, cytotoxic agents may kill stromal cells.(77,170) Although all these mechanisms have been previously examined in preclinical models, their roles in progression-free survival and OS need to be carefully investigated in patients.”
Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “Currently three approaches are in advanced stages of clinical testing that aim to target VEGF/VEGFR signaling pathways: (1) monoclonal antibodies directed against VEGF or its receptor(s) (Winkler et al. 2004; Vredenburgh et al. 2007), (2) small molecule inhibitors of VEGFR-2 tyrosine kinase activity”
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals (2010, background): “Physiological angiogenesis provides a driving force for organ development in ontogeny, is necessary for ovulation, and is a prerequisite for wound healing; pathological angiogenesis occurs during tumor growth at primary and metastatic sites [224].”
Angiogenesis in brain tumours (2007, background): “The proven dependence of tumour growth and metastasis on new vessel formation in animal models has provided a powerful rationale for anti- angiogenic strategies for cancer treatmen”
Interferons at age 50: past, current and future impact on biomedicine (2007, background): “IFNs can also inhibit angiogenesis by altering the stimuli from tumour cells and by directly inhibiting endothelial cells -indeed, they were the first angiogenic inhibitor identified 258 .”
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, unknown): “Blocking tumor angiogenesis would therefore severely restrict tumor growth (Folkman, 2007).”
Vascularization and Angiogenesis in Tissue Engineering: Beyond Creating Static Networks. (2016, background): “Angiopoietin 1 (Ang1) is expressed by vascular mural cells and non-vascular normal and tumor cells [91], and helps to maintain a stable state in vessels [92].”
The therapeutic promise of the cancer stem cell concept. (2010, background): “These findings suggest that vasculogenic mimicry might represent an important survival mechanism that could explain the failure of currently available inhibitors of angiogenesis to fully effect tumor eradication (63).”
A circadian gene expression atlas in mammals: Implications for biology and medicine (2014, methodology): “List of WHO essential medicines were downloaded from the WHO website (18).”
Molecular mechanisms and clinical applications of angiogenesis (2011, background): “To name just a few, insufficient vessel growth or maintenance can lead to stroke, myocardial infarction, ulcerative disorders and neurodegeneration, and abnormal vessel growth or remodelling fuels cancer, inflammatory disorders, pulmonary hypertension and blinding eye disease”
Modes of resistance to anti-angiogenic therapy (2008, unknown): “That this acquired capability is functionally important for manifestation of the disease has been further validated by the approval of angiogenesis inhibitors as cancer therapeutics, most notably ones targeting the vascular endothelial growth factor (VEGF) pro-angiogenic signalling pathway”
Basic and therapeutic aspects of angiogenesis. (2011, unknown): “…causes ischemia in diseases such as myocardial infarction, stroke, and neurodegenerative or obesity-associated disorders, whereas excessive vascular growth or abnormal remodeling promotes many ailments including cancer, inflammatory disorders, and eye disease (Carmeliet, 2003; Folkman, 2007).”
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia (2012, background): “Preclinical studies have shown that inhibition of the vascular endothelial growth factor (VEGF) pathway impedes tumor growth and, clinically, the VEGF-neutralizing antibody Avastin (bevacizumab) and VEGF receptor tyrosine kinase inhibitors (sorafenib and sunitinib) have been used as anticancer treat”
PI3K pathway alterations in cancer: variations on a theme (2008, unknown): “Angiogenesis is critical in tumorigenesis because de novo blood vessel formation must occur to maintain oxygen and nutrient exchange between the tumor periphery and the hypoxic core (Folkman, 2007).”